Antonio Santillan-Gomez, MD
Gynecologic Oncology · San Antonio, TXNPI 1013055813
Payments from drug & device makers
Across 616 payments — averaging $7348.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2.2M
- Tesaro, Inc.$1.3M
- Novartis$535K
- Genentech, Inc.$186K
- Pfizer$97K
- Intuitive Surgical$61K
- plus $152K from 31 others
What the payments were for
- Consulting fees$48,06030%
- Speaking & faculty fees$51,77532%
- Travel & lodging$9,2856%
- Food & beverage$11,2077%
- Education$41,73226%
- Gifts$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 213 | $2,243,333 |
| Tesaro, Inc. | 52 | $1,252,661 |
| Novartis | 9 | $534,927 |
| Genentech, Inc. | 7 | $186,105 |
| Pfizer | 21 | $97,053 |
| Intuitive Surgical | 123 | $61,027 |
| Myriad Genetic Laboratories, Inc. | 65 | $58,391 |
| Karyopharm Therapeutics Inc. | 4 | $36,202 |
| Medical Device Business Services, Inc. | 13 | $28,158 |
| AstraZeneca | 22 | $18,972 |
| Baxter Healthcare | 22 | $4,966 |
| Aspira Women's Health Inc | 4 | $1,849 |
| Johnson & Johnson(2 entities) | 5 | $1,070 |
| Clovis Oncology, Inc. | 8 | $228 |
| AbbVie | 2 | $225 |
| Amgen | 8 | $220 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $216 |
| Eisai Inc. | 4 | $163 |
| Momentis Surgical Inc. | 1 | $157 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| TELA Bio, Inc. | 2 | $105 |
| Boehringer Ingelheim | 1 | $100 |
| Seagen Inc. | 2 | $96 |
| Merck | 4 | $82 |
| Conmed Corporation | 3 | $80 |
| Hologic Sales And Service, LLC | 3 | $73 |
| Puma Biotechnology, Inc. | 3 | $57 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| Tactile Systems Technology Inc | 2 | $33 |
| Meditrina | 1 | $18 |
| Sanofi | 1 | $18 |
| Sobi, Inc | 1 | $18 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $18 |
| Incyte Corporation | 1 | $16 |
| Covidien LP | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$56,146
- PreciseTumor$32,833
- STRATAFIX$24,828
- HARMONIC Product Family$24,828
- ENSEAL Product Family$23,988
- SURGICEL Family of Absorbable Hemostats$23,988
- myChoice CDx$13,599
- myRisk$8,902
- TISSEEL$4,494
- VISTASEAL$3,136
- ETHICON$2,900
- SURGIFLO Hemostatic Matrix$2,900
- DA VINCI SP$2,300
- COLARIS$2,250
- LYNPARZA$2,139
- OVA1$1,800
- ECHELON FLEX Stapler$840
- Hominis Surgical System$157
- UPTRAVI$125
- OPSUMIT$125
How this compares
$4,526,834 in reported general payments places this provider in the 95th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 30 | $256,816 |
| Anastrozole | 35 | $572 |
| Metronidazole | 35 | $363 |
| Megestrol Acetate | 11 | $341 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $279 |
| Tamoxifen Citrate | 12 | $227 |
| Tramadol Hcl | 66 | $187 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 18 | $130 |
| Neomycin Sulfate | 24 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $18,972 | $256,81630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 gynecologic oncology providers in Texas.
Other gynecologic oncology in San Antonio
- Joseph de la GarzaSan Antonio$1M
- Corinne JordanSan Antonio$283K
- Georgia McCannSan Antonio$76K
- James SzenderSan Antonio$36K
- James MarkSan Antonio$6K
- Jaron MarkSan Antonio$6K
- Edward KostSan Antonio$6K
- Pamela SolimanHouston$30.7M
- Noelle ClovenFort Worth$7.3M
- Christine LeeShenandoah$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.